Literature DB >> 26117525

Prognosis of status epilepticus (SE): Relationship between SE duration and subsequent development of epilepsy.

E Santamarina1, M Gonzalez2, M Toledo2, M Sueiras3, L Guzman3, N Rodríguez2, M Quintana4, G Mazuela2, X Salas-Puig2.   

Abstract

UNLABELLED: In animal models, SE duration is related to epileptogenesis. Data in humans are scarce, mainly in NCSE; therefore, we aimed to study the prognosis of SE de novo and which factors may influence subsequent development of epilepsy.
METHODS: We evaluated patients with SE without previous epilepsy at our hospital (February 2011-February 2014), including demographics, etiology, number of AEDs, duration of SE, mortality, and occurrence of seizures during follow-up.
RESULTS: Eighty-nine patients were evaluated. Median age was 69 (19-95) years old. Among them, 33.7% were convulsive. Regarding etiology, 59 were considered acute symptomatic (41 lesions, 18 toxic-metabolic), 17 remote or progressive symptomatic, and 13 cryptogenic. The median recovery time was 24h (30 min-360 h). In-hospital mortality was 29% (n = 26). After a median follow-up of 10 months, 58.7% of survivors (n = 37) showed seizures. Subsequently, we analyzed which factors might be related to the development of epilepsy, and we found that epilepsy development was more frequent with longer SE duration (37 vs. 23 h, p = 0.004); furthermore, patients with a toxic-metabolic etiology developed epilepsy less frequently (33% vs. 67%; p = 0.022). Epilepsy was also correlated (tendency) with focal SE (p = 0.073), a lesion in neuroimaging (p = 0.091), and the use of 2 or more AEDs (p = 0.098). Regarding SE duration, a cutoff of above 24h was clearly related to chronic seizures (p = 0.014); however, combining etiology and duration, the association of longer SE and epilepsy was significant in acute lesional SE (p = 0.034), but not in epilepsy with cryptogenic or remote/progressive etiology. After a logistic regression, only a duration longer than 24h (OR = 3.800 (1.277-11.312), p = 0.016) was found to be an independent predictor of the development of epilepsy.
CONCLUSION: In patients with SE, the longer duration is associated with an increased risk of subsequent epilepsy at follow-up, mainly in symptomatic SE due to an acute lesion. It is unclear if it might be the result of a more severe injury causing both prolonged seizures and subsequent epilepsy, and therefore whether more aggressive treatment in this group might avoid this possibility. Most of the patients with cryptogenic or remote/progressive SE developed epilepsy regardless of SE duration. This article is part of a Special Issue entitled "Status Epilepticus".
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Duration; Epileptogenesis; Status epilepticus

Mesh:

Year:  2015        PMID: 26117525     DOI: 10.1016/j.yebeh.2015.04.059

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  5 in total

Review 1.  Timing is everything: Where status epilepticus treatment fails.

Authors:  Chloe E Hill; Alomi O Parikh; Colin Ellis; Jennifer S Myers; Brian Litt
Journal:  Ann Neurol       Date:  2017-07-29       Impact factor: 10.422

2.  Early treatment with C1 esterase inhibitor improves weight but not memory deficits in a rat model of status epilepticus.

Authors:  Nicole D Schartz; Alexandra L Sommer; Samantha A Colin; Loyda B Mendez; Amy L Brewster
Journal:  Physiol Behav       Date:  2019-10-16

3.  Status epilepticus alert reduces time to administration of second-line antiseizure medications.

Authors:  Mauricio F Villamar; Aaron M Cook; Chenlu Ke; Yan Xu; Jordan L Clay; Katelyn S Dolbec; Rachel Ward-Mitchell; Larry B Goldstein; Meriem Bensalem-Owen
Journal:  Neurol Clin Pract       Date:  2018-12

4.  Prolonged prophylactic effects of gabapentin on status epilepticus-induced neocortical injury.

Authors:  Maria-Belen Perez-Ramirez; Feng Gu; David A Prince
Journal:  Neurobiol Dis       Date:  2020-05-19       Impact factor: 5.996

5.  Involvement of PPARγ in the Anticonvulsant Activity of EP-80317, a Ghrelin Receptor Antagonist.

Authors:  Chiara Lucchi; Anna M Costa; Carmela Giordano; Giulia Curia; Marika Piat; Giuseppina Leo; Jonathan Vinet; Luc Brunel; Jean-Alain Fehrentz; Jean Martinez; Antonio Torsello; Giuseppe Biagini
Journal:  Front Pharmacol       Date:  2017-09-22       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.